Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- PMID: 29808007
- DOI: 10.1038/s41591-018-0036-4
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Abstract
In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity. Understanding the nature of these pathologies and developing treatments for them are hampered by the lack of appropriate animal models. Herein, we describe a mouse model recapitulating key features of CRS and neurotoxicity. In humanized mice with high leukemia burden, CAR T cell-mediated clearance of cancer triggered high fever and elevated IL-6 levels, which are hallmarks of CRS. Human monocytes were the major source of IL-1 and IL-6 during CRS. Accordingly, the syndrome was prevented by monocyte depletion or by blocking IL-6 receptor with tocilizumab. Nonetheless, tocilizumab failed to protect mice from delayed lethal neurotoxicity, characterized by meningeal inflammation. Instead, the IL-1 receptor antagonist anakinra abolished both CRS and neurotoxicity, resulting in substantially extended leukemia-free survival. These findings offer a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.
Comment in
-
Modeling cytokine release syndrome.Nat Med. 2018 Jun;24(6):705-706. doi: 10.1038/s41591-018-0068-9. Nat Med. 2018. PMID: 29808004 No abstract available.
-
Calming the cytokine storm.Nat Rev Immunol. 2018 Jul;18(7):417. doi: 10.1038/s41577-018-0030-6. Nat Rev Immunol. 2018. PMID: 29899366 No abstract available.
Similar articles
-
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.Front Immunol. 2021 Oct 12;12:745320. doi: 10.3389/fimmu.2021.745320. eCollection 2021. Front Immunol. 2021. PMID: 34712233 Free PMC article.
-
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.J Allergy Clin Immunol. 2020 Nov;146(5):940-948. doi: 10.1016/j.jaci.2020.07.025. Epub 2020 Aug 6. J Allergy Clin Immunol. 2020. PMID: 32771558 Review.
-
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.Br J Haematol. 2018 Nov;183(3):364-374. doi: 10.1111/bjh.15644. Epub 2018 Nov 8. Br J Haematol. 2018. PMID: 30407609 Review.
-
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.Nat Med. 2018 Jun;24(6):731-738. doi: 10.1038/s41591-018-0041-7. Epub 2018 May 28. Nat Med. 2018. PMID: 29808005 Free PMC article.
-
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5. Oncologist. 2018. PMID: 29622697 Free PMC article.
Cited by
-
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.Acta Pharm Sin B. 2024 Jun;14(6):2361-2377. doi: 10.1016/j.apsb.2024.03.027. Epub 2024 Mar 24. Acta Pharm Sin B. 2024. PMID: 38828136 Free PMC article. Review.
-
Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb.Pharmaceuticals (Basel). 2024 May 6;17(5):591. doi: 10.3390/ph17050591. Pharmaceuticals (Basel). 2024. PMID: 38794161 Free PMC article. Review.
-
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.Int J Mol Sci. 2024 May 14;25(10):5361. doi: 10.3390/ijms25105361. Int J Mol Sci. 2024. PMID: 38791398 Free PMC article. Review.
-
Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors.Cell Death Dis. 2024 May 24;15(5):359. doi: 10.1038/s41419-024-06734-2. Cell Death Dis. 2024. PMID: 38789450 Free PMC article. Review.
-
Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies.Nat Commun. 2024 May 24;15(1):4444. doi: 10.1038/s41467-024-48653-y. Nat Commun. 2024. PMID: 38789421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources